目的 探討強(qiáng)肝膠囊聯(lián)合復(fù)方二氯醋酸二異丙胺治療慢性乙型肝炎的臨床療效。方法 回顧性分析2021年6月-2023年6月河南中醫(yī)藥大學(xué)第一附屬醫(yī)院消化內(nèi)科收治的100例慢性乙型肝炎患者的臨床資料,根據(jù)治療方式不同將患者分為對照組和治療組,每組各50例。對照組患者靜脈滴注復(fù)方二氯醋酸二異丙胺注射液,40 mg/次,用0.9%氯化鈉溶液100 mL稀釋,1次/d。治療組在對照組的治療基礎(chǔ)上口服強(qiáng)肝膠囊,3粒/次,3次/d。兩組連續(xù)治療30 d。觀察兩組的臨床療效和臨床癥狀緩解時間,比較治療前后兩組肝功能指標(biāo)和血清炎性因子水平的變化情況。結(jié)果 治療后,治療組總有效率是98.00%,顯著高于對照組的82.00%(P<0.05)。治療后,治療組出現(xiàn)的乏力、腹脹、畏食、肝區(qū)疼痛緩解時間均短于對照組(P<0.05)。治療后,兩組總膽紅素(TBil)、丙氨酸轉(zhuǎn)氨酶(ALT)、天冬氨酸氨基轉(zhuǎn)氨酶(AST)均較同組治療前顯著降低(P<0.05);治療后,治療組肝功能指標(biāo)顯著低于對照組(P<0.05)。治療后,兩組患者白細(xì)胞介素17(IL-17)、轉(zhuǎn)化生長因子β1(TGF-β1)、基質(zhì)金屬蛋白酶組織抑制物-1(TIMP-1)水平均顯著低于同組治療前,而干擾素-γ(INF-γ)水平高于治療前(P<0.05);治療后,治療組血清學(xué)指標(biāo)改善優(yōu)于對照組(P<0.05)。結(jié)論 強(qiáng)肝膠囊聯(lián)合復(fù)方二氯醋酸二異丙胺治療慢性乙型肝炎效果確切,能加快臨床癥狀有效緩解,并促進(jìn)肝功能有效好轉(zhuǎn),使機(jī)體局部炎性反應(yīng)減弱,值得臨床借鑒應(yīng)用。

Objective To explore the clinical effect of Qianggan capsule combined with compound diisopropylamine dichloroacetate in treatment of chronic hepatitis B. Methods Clinical data of 100 patients with chronic hepatitis B admitted to the Department of Gastroenterology of the First Affiliated Hospital of Henan University of Chinese Medicine from June 2021 to June 2023 were retrospectively analyzed. The patients were divided into control group and treatment group according to different treatment methods, with 50 cases in each group. Patients in the control group were iv administered with Compound Diisopropylamine Dichloroacetate Injection, 40 mg/time, diluted with 0.9% sodium chloride solution 100 mL, once daily. Patients in the treatment group were po administered with Qianggan Capsules on the basis of the control group, 3 grains/time, 3 times daily. Both groups were treated continuously for 30 d. The clinical efficacy and duration of clinical symptom remission were observed, and the changes of liver function indexes and serum inflammatory factors before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 98.00%, which was significantly higher than that of the control group (82.00%, P < 0.05). After treatment, the time of fatigue, abdominal distension, fear of eating and relief of liver pain in the treatment group were shorter than those in the control group (P < 0.05). After treatment, total bilirubin (TBil), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the liver function index of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the levels of interleukin17 (IL-17), transforming growth factor β1 (TGF-β1) and matrix metalloproteinase-1 (TIMP-1) in 2 groups were significantly lower than before treatment, while the levels of interferon-γ (INF-γ) were higher than before treatment (P < 0.05). After treatment, the improvement of serological indexes in treatment group was better than that in control group (P < 0.05). Conclusion Qianggan Capsule combined with compound diisopropylamine has accurate effect in treatment of chronic hepatitis B, and can accelerate the effective relief of clinical symptoms, promote the effective improvement of liver function, weaken the local inflammatory response of the body, which is worthy of clinical application.

R975